Nelly Group Q4 report was solid but mixed, with net sales of SEK 371m, up 16% y/y (5% ahead of SEB),...
Redeye returns with an update following Ascelia Pharma's Q4 update, which contained no material surp...
Enersense and Finnish energy company Helen have agreed to extend their operations and maintenance ag...
Redeye comments on Hacksaw ahead of Q4-results (due 17 February) where we expect continued solid gro...
Relais outperformed the market in Q3 and we expect a similar performance for Q4.
The Leipurin segment was divested in August 2025 and ESL Shipping could be sold this year.
Redeye provides a preview of Catella ahead of the company's Q4 2025 results, scheduled for 17 Februa...
* We expect broad-based organic growth * Q4e net sales of SEK 193m, EBITA of SEK 25m * We reiterate ...
* Q4 EBITDA of NOK 5m * Awaiting improved markets * '26e-'27e estimates down – fair value range of N...
We expect a noticeable improvement in Gofore’s margin performance in Q4.
Koppar, silver och guld återfinns i Bluelakes huvudprojekt Joma och Stekenjokk-Levi.
Ahead of Atria's Q4 report, we maintain our estimates intact.
EQL Pharma rapporterade ett starkt Q3 2025/26 med rekordomsättning och en tydlig lönsamhetsförbättri...
Hyresintäkterna steg 49% till 61,7 MEUR tack vare stora polska förvärv, högre uthyrning och indexeri...
Redeye briefly comments on the Q4 royalties for Leqembi, which came in roughly as expected.
Redeye provides a short comment on the Q4 report. We also highligt that following the acquisitions o...
Consti’s outlook for 2026 was on the softer side, with the challenging market conditions not showing...
YIT as expected saw a return to growth in Q4 and healthy profitability figures.
Investors House reported Q4 revenues of EUR 1.8m, 9% above our estimate.
Redeye updates its estimates and valuation after Lagercrantz’s Q3 2025/2026 report.